Young Hwan Chang

Dr. Young Hwan Chang

Oregon Health & Science University, Portland, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Cell
Verified
Journal Article
Closed access
FRFlorian Rambow
Florian Rambow
ARAljosja Rogiers
Aljosja Rogiers
OMOskar Marin-Bejar
Oskar Marin-Bejar
SASara Aibar
Sara Aibar
JFJulia Femel
Julia Femel
JMJean-Christophe Marine
Jean-Christophe Marine

1 April 2017 in Cell Reports
Verified
Journal Article
Open access
TTTakahiro Tsujikawa
Takahiro Tsujikawa
SKSushil Kumar
Sushil Kumar
RBRohan N. Borkar
Rohan N. Borkar
VAVahid Azimi
Vahid Azimi
GTGuillaume Thibault
Guillaume Thibault
LCLisa M. Coussens
Lisa M. Coussens
Here, we describe a multiplexed immunohistochemical platform with computational image processing workflows, including image cytometry, enabling simultaneous evaluation of 12 biomarkers in one formalin-fixed paraffin-embedded tissue section. To validate this platform, we used tissue microarrays containing 38 archival head and neck squamous cell carcinomas and revealed differential immune profiles based on lymphoid and myeloid cell densities, correlating with human papilloma virus status and prognosis. Based on these results, we investigated 24 pancreatic ductal adenocarcinomas from patients who received neoadjuvant GVAX vaccination and revealed that response to therapy correlated with degree of mono-myelocytic cell density and percentages of CD8+ T cells expressing T cell exhaustion markers. These data highlight the utility of in situ immune monitoring for patient stratification and provide digital image processing pipelines to the community for examining immune complexity in precious tissue sections, where phenotype and tissue architecture are preserved to improve biomarker discovery and assessment.

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
ELEllen M. Langer
Ellen M. Langer
BABrittany Allen-Petersen
Brittany Allen-Petersen
SKShelby M. King
Shelby M. King
NKNicholas D. Kendsersky
Nicholas D. Kendsersky
MTMegan A. Turnidge
Megan A. Turnidge
RSRosalie C. Sears
Rosalie C. Sears
The tumor microenvironment plays a critical role in tumor growth, progression, and therapeutic resistance, but interrogating the role of specific tumor-stromal interactions on tumorigenic phenotypes is challenging within in vivo tissues. Here, we tested whether three-dimensional (3D) bioprinting could improve in vitro models by incorporating multiple cell types into scaffold-free tumor tissues with defined architecture. We generated tumor tissues from distinct subtypes of breast or pancreatic cancer in relevant microenvironments and demonstrate that this technique can model patient-specific tumors by using primary patient tissue. We assess intrinsic, extrinsic, and spatial tumorigenic phenotypes in bioprinted tissues and find that cellular proliferation, extracellular matrix deposition, and cellular migration are altered in response to extrinsic signals or therapies. Together, this work demonstrates that multi-cell-type bioprinted tissues can recapitulate aspects of in vivo neoplastic tissues and provide a manipulable system for the interrogation of multiple tumorigenic endpoints in the context of distinct tumor microenvironments.

31 October 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RLRyan S. Lane
Ryan S. Lane
JFJulia Femel
Julia Femel
ABAlec P. Breazeale
Alec P. Breazeale
CLChristopher P. Loo
Christopher P. Loo
GTGuillaume Thibault
Guillaume Thibault
ALAmanda W. Lund
Amanda W. Lund
Mechanisms of immune suppression in peripheral tissues counteract protective immunity to prevent immunopathology and are coopted by tumors for immune evasion. While lymphatic vessels facilitate T cell priming, they also exert immune suppressive effects in lymph nodes at steady-state. Therefore, we hypothesized that peripheral lymphatic vessels acquire suppressive mechanisms to limit local effector CD8+ T cell accumulation in murine skin. We demonstrate that nonhematopoietic PD-L1 is largely expressed by lymphatic and blood endothelial cells and limits CD8+ T cell accumulation in tumor microenvironments. IFNγ produced by tissue-infiltrating, antigen-specific CD8+ T cells, which are in close proximity to tumor-associated lymphatic vessels, is sufficient to induce lymphatic vessel PD-L1 expression. Disruption of IFNγ-dependent crosstalk through lymphatic-specific loss of IFNγR boosts T cell accumulation in infected and malignant skin leading to increased viral pathology and tumor control, respectively. Consequently, we identify IFNγR as an immunological switch in lymphatic vessels that balances protective immunity and immunopathology leading to adaptive immune resistance in melanoma. Graphical Abstract

1 September 2018 in Automatica
Verified
Journal Article
Closed access
YCYoung Hwan Chang
Young Hwan Chang
QHQie Hu
Qie Hu
CTClaire J. Tomlin
Claire J. Tomlin

27 February 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MSMaria M. Steele
Maria M. Steele
AJAbhinav Jaiswal
Abhinav Jaiswal
IDInes Delclaux
Ines Delclaux
IDIan D. Dryg
Ian D. Dryg
DMDhaarini Murugan
Dhaarini Murugan
ALAmanda W. Lund
Amanda W. Lund